The promises and perils of psychedelic pharmacology for psychiatry

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

(2021) Nakul Ravi Raval et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Psychedelic-inspired drug discovery using an engineered biosensor

(2021) Chunyang Dong et al.   CELL

New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review

(2021) Fabrizio Schifano et al.   EXPERIMENTAL NEUROLOGY

Trial of Psilocybin versus Escitalopram for Depression

(2021) Robin Carhart-Harris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice

(2021) Natalie Hesselgrave et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1

(2021) Ramona M. Rodriguiz et al.   Scientific Reports

Psychedelics and Psychedelic-Assisted Psychotherapy

(2020) Collin M. Reiff et al.   AMERICAN JOURNAL OF PSYCHIATRY

Virtual discovery of melatonin receptor ligands to modulate circadian rhythms

(2020) Reed M. Stein et al.   NATURE

Psychedelic Psychiatry’s Brave New World

(2020) David Nutt et al.   CELL

TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome

(2020) Reid H. J. Olsen et al.   Nature Chemical Biology

Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species

(2020) Adam L. Halberstadt et al.   NEUROPHARMACOLOGY

Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders

(2020) Ege T. Kavalali et al.   NEURON

Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor

(2020) Kuglae Kim et al.   CELL

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

(2020) Friederike Holze et al.   NEUROPSYCHOPHARMACOLOGY

Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays

(2020) Eline Pottie et al.   BIOCHEMICAL PHARMACOLOGY

A non-hallucinogenic psychedelic analogue with therapeutic potential

(2020) Lindsay P. Cameron et al.   NATURE

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

(2020) Alan K. Davis et al.   JAMA Psychiatry

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

(2019) Martin K. Madsen et al.   NEUROPSYCHOPHARMACOLOGY

Ultra-large library docking for discovering new chemotypes

(2019) Jiankun Lyu et al.   NATURE

Serotonin transporter–ibogaine complexes illuminate mechanisms of inhibition and transport

(2019) Jonathan A. Coleman et al.   NATURE

Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs

(2019) Bryan L. Roth   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Dark Classics in Chemical Neuroscience: Mescaline

(2018) Bruce K. Cassels et al.   ACS Chemical Neuroscience

Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor

(2018) Tao Che et al.   CELL

5-HT 2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology

(2018) Yao Peng et al.   CELL

Psychedelics Promote Structural and Functional Neural Plasticity

(2018) Calvin Ly et al.   Cell Reports

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

(2018) Leor Roseman et al.   Frontiers in Pharmacology

Psilocybin and Mental Health–Don't Lose Control

(2018) Joseph M. Barnby et al.   Frontiers in Psychiatry

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor

(2018) Katrin H Preller et al.   eLife

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

(2017) R. L. Carhart-Harris et al.   PSYCHOPHARMACOLOGY

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

(2016) Anna Rickli et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Psilocybin for depression and anxiety associated with life-threatening illnesses

(2016) John D McCorvy et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

(2016) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

(2016) Stephen Ross et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Analysis of protein-coding genetic variation in 60,706 humans

(2016) Monkol Lek et al.   NATURE

PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome

(2015) Wesley K Kroeze et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Alucinógenos en las culturas precolombinas mesoamericanas

(2015) F.J. Carod-Artal   NEUROLOGIA

Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)

(2015) Anna Rickli et al.   NEUROPHARMACOLOGY

PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome

(2015) Wesley K Kroeze et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Synthesis and Structure–Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists

(2014) Martin Hansen et al.   ACS Chemical Neuroscience

Serotonin 2A Receptor Agonist Binding in the Human Brain with [11C]Cimbi-36

(2014) Anders Ettrup et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice

(2014) William E. Fantegrossi et al.   PSYCHOPHARMACOLOGY

Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on   Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations

(2013) M. Kometer et al.   JOURNAL OF NEUROSCIENCE

Structural Features for Functional Selectivity at Serotonin Receptors

(2013) D. Wacker et al.   SCIENCE

Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’)

(2012) François Montastruc et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model

(2012) Clint E. Canal et al.   Drug Testing and Analysis

A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?1

(2011) Brian P. Akers et al.   ECONOMIC BOTANY

Signaling pathways underlying the rapid antidepressant actions of ketamine

(2011) Ronald S. Duman et al.   NEUROPHARMACOLOGY

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

(2010) Matthew W. Johnson et al.   DRUG AND ALCOHOL DEPENDENCE

Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a  -Arrestin2/Src/Akt Signaling Complex In Vivo

(2010) C. L. Schmid et al.   JOURNAL OF NEUROSCIENCE

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

(2010) Erich Studerus et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors

(2009) A. I. Abbas et al.   JOURNAL OF NEUROSCIENCE

Predicting new molecular targets for known drugs

(2009) Michael J. Keiser et al.   NATURE

Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling

(2009) K. A. Jones et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

(2008) W. J. Thomsen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The 5-HT3 receptor – the relationship between structure and function

(2008) Nicholas M. Barnes et al.   NEUROPHARMACOLOGY

Opportunities and Challenges of Psychiatric Drug Discovery: Roles for Scientists in Academic, Industry and Government Settings

(2008) P Jeffrey Conn et al.   NEUROPSYCHOPHARMACOLOGY

Agonist-directed signaling of the serotonin 2A receptor depends on  -arrestin-2 interactions in vivo

(2008) C. L. Schmid et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structure and Function of the Third Intracellular Loop of the 5-Hydroxytryptamine2A Receptor: The Third Intracellular Loop Is α-Helical and Binds Purified Arrestins

(2003) Edward I. Gelber et al.   JOURNAL OF NEUROCHEMISTRY